Mobile phones do not cause eye cancer

Article

The use of mobile telephones does not increase the risk of uveal melanoma, according to a study published online ahead of print by the Journal of the National Cancer Institute.

The use of mobile telephones does not increase the risk of uveal melanoma, according to a study published online ahead of print by the Journal of the National Cancer Institute.

Andreas Stang, MD, MPH of the Martin Luther University of Halle-Wittenberg, Halle, Germany and colleagues conducted a case-control study of uveal melanoma patients (n=459) and control subjects (n=1194) drawn from the general population, melanoma patients’ siblings and ophthalmologists’ offices. The team used a questionnaire to assess any correlation between melanoma and self-assessed mobile phone use (regular, sporadic and never).

The researchers found that, even among regular mobile telephone users, the incidence of uveal melanoma development was similar to that among the control group: odds ratio (OR) = 0.7, 95% confidence interval (CI) = 0.5 to 1.0 versus population control subjects; OR = 1.1, 95% CI = 0.6 to 2.3 versus ophthalmologist control subjects; and OR = 1.2, 95% CI =0.5 to 2.6 versus sibling control subjects.

Thus the researchers concluded that, up to ten years, mobile telephone use is not correlated with an increased risk of uveal melanoma. This conclusion is in contrast to earlier study results showing a relationship between mobile phone exposure and melanoma development.

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.